News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Strategic Research Institute Release: Cox-2 Safety Concerns Spur Renewed Pharma Interest In Research For New Drugs To Treat Inflammatory Diseases

10/19/2005 5:12:42 PM

PHILADELPHIA, Feb. 11 /PRNewswire/ -- The recent safety concerns surrounding the well-know anti-inflammatory drugs Vioxx and Celebrex have caused many pharmaceutical companies to renew research in inflammation in search of effective new drugs to treat osteoarthritis as the Cox-2 class has been irremediably tainted, physicians reluctant to prescribe, and patients reluctant to take. Though Pfizer has kept Celebrex on the market, sales have dropped dramatically.

The search for new targets has hastened the entry of many new companies and old ones, the latter having abandoned their efforts after the first Cox-2 drugs were approved about 5 years ago. Many of the companies will be attending the 9th International Inflammation & Immune Diseases Drug Discovery & Development Summit on March 14-15, 2005 in Philadelphia, which is considered to be the premier networking and information meeting among the pharmaceutical and biotechnology communities. This year's meeting brings together the world industrial community of immunology & inflammatory researchers for the annual review on their programs intended to generate next generation drugs, announces Strategic Research Institute.

The agenda offers a tracked session on Inflammation or Immune Diseases and features keynote presentations by Charles Dinarello, M.D., from the University of Colorado and Peter Lipsky, M.D., from the NIH (National Institutes of Health). The following highlighted keynotes are listed in detail below:

Anti-Cytokine Therapies for Treating Human Disease Charles A. Dinarello, M.D. Professor of Medicine UNIVERSITY OF COLORADO HEALTH SCIENCE CENTER Corticosteroids - The Next Generation Iain Uings, Ph.D. Section Head, Rheumatoid Arthritis Pharmacology GLAXOSMITHKLINE Role of B Cells in Autoimmune Diseases Peter E. Lipsky, M.D. Director, Intramural Research Program - Arthritis, Musculoskeletal & Skin Diseases NATIONAL INSTITUTES OF HEALTH (NIH)

Complete and updated list of presenting companies and institutions includes: Abbott Bioresearch Center, Amgen, Inc. -- San Francisco (Formerly Tularik), Amgen, Inc. -- Seattle (Formerly Immunex), AstraZeneca, AstraZeneca R&D Charnwood, UK, Biovation Ltd., UK, Biogen Idec, Celgene Corporation, Celgene San Diego, Chemocentryx, Galapagos Genomics, GlaxoSmithKline, Incyte Corporation, Isis Pharmaceuticals, MD Biosciences, Merck Research Laboratories, Millennium Pharmaceuticals, Novartis Pharmaceuticals, Pfizer Global Research & Development, Pharmacopeia, Protein Design Labs, Rigel, Inc., Sangamo Biosciences, Sanofi Aventis, Vertex Pharmaceuticals, Wyeth Discovery Research, Lakeshore Medical Clinic, National Institutes of Health (NIH), The Rayne Institute, University of Colorado Health Science Center, University of Glasgow, & University of Sheffield, UK.

To receive the full agenda in PDF, please contact Ed Drilon of Strategic Research Institute at or 212-967-0095, x233 (please include name and corporate affiliation).

Leverage our strong position in the industrial inflammatory and immune diseases area to showcase your products and services to this high-level, targeted audience of pharmaceutical scientists and executive decision makers. To inquire about sponsorship & exhibition opportunities, please contact Mark Alexay at LUNCHEON SPEAKING OPPORTUNITIES FOR BOTH DAYS REMAIN AVAILABLE.

To become a media partner, please contact Cheryl Kahan-Radhuber at

Strategic Research Institute

CONTACT: Ed Drilon of Strategic Research Institute, +1-212-967-0095x233,

Read at

comments powered by Disqus